#### CANCER GENETICS, INC

Form 4 May 18, 2015

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** Form 4 or

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b). (Print or Type Responses)

(Last)

1. Name and Address of Reporting Person \* PRENDERGAST FRANKLYN G

2. Issuer Name and Ticker or Trading Symbol

CANCER GENETICS, INC [CGIX]

3. Date of Earliest Transaction

05/14/2015

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

10% Owner

Other (specify

**OMB** 

Number:

Expires:

response...

Estimated average

burden hours per

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

(Month/Day/Year) 201 ROUTE 17 NORTH, 2ND

(Middle)

FLOOR, C/O CANCER GENETICS, INC.

(Street)

(First)

Security

(Instr. 3)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X\_ Director

Officer (give title

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

below)

RUTHERFORD, NJ 07070

(City) (State) (Zip) 1. Title of 2. Transaction Date 2A. Deemed

(Month/Day/Year) Execution Date, if

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of Securities Beneficially Owned Following

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial (I) Ownership (Instr. 4) (Instr. 4)

Reported (A) Transaction(s) or (Instr. 3 and 4)

Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Conversion 3. Transaction Date 3A. Deemed

(Month/Day/Year) Execution Date, if

5. Number of TransactionDerivative

6. Date Exercisable and **Expiration Date** 

7. Title and Amount of Underlying Securities

### Edgar Filing: CANCER GENETICS, INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security	any (Mo	ny Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year	)	(Instr. 3 and 4	4)
				Code V	(A) (D)	) Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to	\$ 10.74	05/14/2015		A	10,000	05/14/2016(1)	05/14/2025	Common Stock	10,000

### **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

PRENDERGAST FRANKLYN G

201 ROUTE 17 NORTH, 2ND FLOOR
C/O CANCER GENETICS, INC.

RUTHERFORD, NJ 07070

### **Signatures**

buy)

/s/ Franklyn Prendergast by Edward J. Sitar, Attorney in Fact 05/14/2015

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in two equal installments on May 14, 2016 and May 14, 2017, respectively.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2